The IPASS trial was the first randomized phase III trial evaluating the efficacy of gefitinib versus chemotherapy (carboplatin/docetaxel) in 1217 treatment-naïve EGFR-mutated NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.